Sentences with phrase «cell disease therapy»
Novo Nordisk Obtains Worldwide Rights to EpiDestiny's Sickle Cell Disease Therapy - Sickle Cell Anemia News
http://www.innovationtoronto.com/ Not exact matches
«The better we understand these cell types and how they affect disease, the better we will be able to develop new therapies to treat and cure disease.»
I admire SQZ Biotech's unique platform — they're on the forefront of something huge that has the potential to revolutionize disease research and cell therapy.
Venter reiterated this sentiment: «Using the combined power of our core areas of expertise — genomics, informatics, and stem cell therapies, we are tackling one of the greatest medical / scientific and societal challenges — aging and aging related diseases,» he said in a statement.
About Nohla Therapeutics Nohla Therapeutics is a leading developer of off - the shelf cell therapies for the treatment of cancer and other critical diseases.
His research has spanned hematopoiesis, gene therapy, stem cell biology, genomics and cancer, consistently focusing on bringing the very latest research advances to patients with heretofore incurable diseases.
Instead of getting a better, updated therapy for a disease every decade or so, we might begin to see second - generation cell therapies in a few years.
«Using the combined power of our core areas of expertise — genomics, informatics, and stem cell therapies, we are tackling one of the greatest medical / scientific and societal challenges — aging and aging related diseases,» said Dr. Venter.
Using advances in genomic sequencing, the human microbiome, proteomics, informatics, computing, and cell therapy technologies, HLI is building the world's most comprehensive database of human genotypes and phenotypes as a basis for a variety of commercialization opportunities to help solve aging related disease and human biological decline.
The Chiesi fund will consider a wide range of opportunities, from traditional small molecules and biologics, to gene therapies and cell therapies, to diagnostic and disease management technologies.
Cambridge, MA — March 30, 2017 — Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells using viral nanoparticle conjugates, announced today that it has enrolled and dosed the first patient in its Phase 1b clinical trial of light - activated AU - 011, an investigational, first - in - class targeted therapy in development for the treatment of ocular melanoma, a rare and life - threatening disease.
What Stephen Hawking Missed: Small Biotechs Developing Promising Cell Therapies for Devastating Disease Source: Streetwise Reports (5/2/18) In the second of a two - part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small - cap companies targeting big - ticket indications and their potential to drive blockbuster value for both patients and investCell Therapies for Devastating Disease Source: Streetwise Reports (5/2/18) In the second of a two - part series exploring the disruptive cell therapy space, Maxim Group analyst Jason McCarthy takes a look at small - cap companies targeting big - ticket indications and their potential to drive blockbuster value for both patients and investcell therapy space, Maxim Group analyst Jason McCarthy takes a look at small - cap companies targeting big - ticket indications and their potential to drive blockbuster value for both patients and investors.
For instance, specific anti-T-cell therapies don't work at all for rheumatoid arthritis (RA), and Edwards doesn't think T - cells explained how the disease persisted.
«In effort to treat rare blinding disease, researchers turn stem cells into blood vessels: Patients around the world contribute skin samples to test potential new therapy.»
They isolated blood cells from HIV - positive patients on antiretroviral therapy and at different stages of disease progression, as well as cells from non-infected individuals.
«Step toward gene therapy for sickle cell disease.»
Increasingly, though, better techniques are raising hopes for practical therapies that can permanently cure genetic diseases like sickle cell.
ORDINARY cells from people with a genetic disease can be «fixed» by gene therapy and then reprogrammed to be stem cells that will produce a limitless supply of defect - free cells.
«Cultural revolution in the study of the gut microbiome: Human gut - on - a-chip technology used to co-culture gut microbiome, human intestinal cells could lead to new therapies for inflammatory bowel diseases.»
A team of researchers at the Stanford University School of Medicine has used a gene - editing tool known as CRISPR to repair the gene that causes sickle cell disease in human stem cells, which they say is a key step toward developing a gene therapy for the disorder.
«This research has broad impact, because by deepening our understanding of cell reprogramming we have the potential to improve disease modeling and the generation of better sources of patient - specific specialized cells suitable for replacement therapy,» said Plath.
However, there is still limited data on the short and long - term effects of administering stem cell therapy in chronic respiratory disease.
We believe that they will also lead to the development of a whole new range of therapies for neurodegenerative diseases of the central nervous system,» explains corresponding author of the study Jihwan Song, professor and director of Neural Regeneration and Therapy Group at the CHA Stem Cell Institute of CHA University.
A new study has found that stem cell therapy can reduce lung inflammation in an animal model of chronic obstructive pulmonary disease (COPD) and cystic fibrosis.
Tissue engineering provides a more practical means for researchers to study cell behavior, such as cancer cell resistance to therapy, and test new drugs or combinations of drugs to treat many diseases.
Rashid's ultimate hope is that one day scientsts will be able to correct the diseased cells in the lab and transplant them back into the patient, but he cautions that cell - based therapies won't be available anytime soon.
Researchers at the University of Louisville have discovered a mechanism involved in skeletal muscle repair that may enable clinicians to boost the effectiveness of adult stem cell therapies for diseases such as muscular dystrophy.
Realistic stem cell therapies to replace diseased or damaged tissue may still be years away, but researchers have uncovered a promising new use for these undifferentiated cells: they can be programmed to become patient - specific laboratory models of inherited liver disease.
But scientists are making progress in refining these therapies, and the first ever trial of fetal stem cells injected directly into the brain is currently under way in children with Batten disease, a rare and fatal illness of the nervous system.
«Our study reveals a new mechanism that could be harnessed for biological therapies for lupus and other autoimmune diseases, where the immune system mistakenly targets the body's own cells,» says senior study author Boris Reizis, PhD, professor of Pathology and Medicine at NYU Langone.
«Due to the inhibitory function of Treg cells, people have been trying to use these cells for therapy in human autoimmune diseases or transplantation,» explains professor Yun Cai Liu, Ph.D., who led the current study.
New products and developments, such as new drugs for cancer, fresh therapies for rare diseases, progress in medications for HIV / AIDS, and advances in stem cell research had the greatest positive impact.
Eye diseases — such as age - related macular degeneration, as well as a genetic condition called Stargardt's macular dystrophy that afflicts young people — are considered excellent candidates for stem cell therapy because the eye is an immune - privileged site, meaning transplanted cells are not as likely to be rejected as foreign compared with transplants elsewhere.
«Stem cell gene therapy could be key to treating Duchenne muscular dystrophy: Approach developed at UCLA holds promise for 60 percent of patients with the deadly disease.»
This accomplishment opens the door for disease modeling and drug screening and brings personalized cell therapy a step closer for patients with diabetes.
Diabetes researchers are considering various replacements for insulin injections: Transplanting new pancreatic islet cells that make insulin, coaxing the patient's own islets to regenerate, or treating diabetics early in the disease with immune - suppressing therapies to prevent their body from destroying the rest of their pancreatic islets.
The stem cell gene therapy could be applicable for 60 percent of people with Duchenne, which affects approximately 1 in 5,000 boys in the U.S. and is the most common fatal childhood genetic disease.
These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.
Additionally, work in a mouse model revealed similar cells, indicating that the progenitors are conserved from mouse to human, and therefore, they must be «important cells with promising potential for cell therapy in treating liver disease,» explained Dr. Gouon - Evans.
For his part, Collins, who has led NIH since 2009 and been kept on by the Trump administration, pointed to an array of promising NIH activities, including the development of new technologies to provide insights into human brain circuitry and function through the Brain Research through Advancing Innovative Neuroethologies (BRAIN initiative) and the use of the gene - editing tool CRISPR - Cas9 to correct mutations and clear the way to develop and test a «curative therapy» for the first molecular disease: sickle cell disease.
Researchers can create iPSCs from a patient's blood or skin cells, and use these patient - specific cells to study diseases or even create new tissues that could be transplanted back into the patient as therapy.
«It's fantastic news that they are going into the clinic with a cell therapy for eye disease,» says Pete Coffey of University College London, and head of a team developing tiny «patches» of RPEs for treating age - related macular degeneration.
«If you want to develop a therapy for autoimmune diseases, the idea is, How do we get Xist to the inactive X chromosome and keep it there so we maintain dosage compensation in these B cells.»
A specific genetic marker influences response to therapy in the early stages of RA; a link thought to be due to the gene activating a cell - signalling protein involved in the inflammatory disease process.
The technology and its resulting research also may become of great value in medical laboratories and hospitals in improving the detection and diagnosis of diseased cells and in evaluating a patient's response to therapy.
In addition to providing insights regarding selection of treatment, this blood test may also prove helpful in assessing the presence of residual disease, recurrence, or relapse and detection of therapy - resistant cancer cells more quickly than conventional tissue - based methods.
«Our findings could have a significant impact on the treatment of autoimmune diseases, as well as on stem cell and immuno - oncology therapies,» said Gladstone Senior Investigator Sheng Ding, PhD, who is also a professor of pharmaceutical chemistry at the University of California, San Francisco.
«By reprogramming human cells, scientists have created new opportunities to study diseases and develop methods for diagnosis and therapy,» the Nobel judges wrote.
Combining radiation therapy with chemotherapy for patients with limited metastatic non-small cell lung cancer (NSCLC) may curb disease progression dramatically when compared to NSCLC patients who only receive chemotherapy, according to a new randomized phase II clinical trial reported today at the 59th Annual Meeting of the American Society for Radiation Oncology (ASTRO).
«Investigators create complex kidney structures from human stem cells derived from adults: New technique offers model for studying disease, progress toward cell therapy.»